polatuzumab fda approval in dlbcl (polarix) & swog s1826 nivo vs. bv in hodgkin's lymphoma
Published 1 year ago • 2.3K plays • Length 21:26Download video MP4
Download video MP3
Similar videos
-
24:57
how to treat diffuse large b-cell lymphoma (dlbcl) - dr. carla casulo
-
0:43
summary of two important lymphoma studies - polarix andd swog s1826 #oncology #cancer #lymphoma
-
1:00:51
update on relapsed/refractory diffuse large b-cell lymphoma | lymphoma research foundation webinars
-
9:16
understanding diffuse large b-cell lymphoma
-
4:54
understanding diffuse large b-cell lymphoma (dlbcl)
-
0:55
results of polarix trial #oncology #cancer #2023
-
0:59
polarix study design which led to the approval of polatuzumab #oncology #cancer #2023
-
29:00
dlbcl in 2023: top docs discuss the latest in diffuse large b-cell lymphoma | treatments & research
-
0:58
polatuzumab in diffuse large b-cell lymphoma
-
26:17
how to treat follicular & mantle cell lymphomas - discussion with dr. pallawi torka
-
36:47
all about tumor lysis syndrome in dlbcl
-
2:26
the current approaches to treating dlbcl in the frontline and relapsed settings
-
6:44
prognostic factors in dlbcl
-
20:52
colon cancer algorithm discussion with oncology brothers (rohit & rahul gosain) and dr. cathy eng
-
3:10
clinical trials and research for diffuse large b-cell lymphoma
-
5:30
how the treatment landscape of dlbcl is changing: r-chop vs pola-r-chp
-
2:14
how does biomarker testing impact dlbcl treatment options?
-
2:08
the current and future role of bispecifics in r/r dlbcl: epcoritamab, glofitamab & more
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
31:39
lymphoma | 2022 oneoncology conference
-
5:26
treatment options for diffuse large b-cell lymphoma (dlbcl)
-
1:05
where do bispecific antibodies fit into the large cell lymphoma treatment landscape?